Tomocube Inc
Tomocube Inc is a South Korean company specializing in the development and production of advanced medical equipment and technology, primarily focused on diagnostic imaging systems and related healthcare solutions.
Business. Tomocube Inc (475960.KQ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. Tomocube is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Tomocube Inc (475960.KQ) is a healthcare company specializing in advanced medical equipment and technology. The firm operates within the Healthcare Services & Equipment industry, focusing on the development and sale of healthcare equipment. Tomocube is headquartered in South Korea and is primarily listed on the KOSDAQ exchange. Specific details regarding operating segments and geographic revenue mix are not disclosed.
Tomocube's capital structure is characterized by a high liquidity position, with cash and equivalents amounting to KRW 11,449,134,440, which is significantly higher than its total liabilities of KRW 2,717,675,800. The company's liquidity ratio of 23.15 indicates a strong ability to meet short-term obligations. However, the company's price-to-book ratio of 16.04 suggests that the market is valuing the company at a premium relative to its book value, which may reflect expectations of future growth or innovation.
Profitability metrics for Tomocube are currently negative, with a net loss of KRW 4,810,012,370 and an operating loss of KRW 5,567,639,090. The return on equity (ROE) is -12.4%, and the return on assets (ROA) is -11.59%, both of which are significantly below the industry median for the Advanced Medical Equipment & Technology sector. These figures indicate that the company is not generating returns for shareholders or effectively utilizing its assets.
The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no material geographic diversification reported. This lack of diversification increases the company's exposure to market-specific risks, particularly in the South Korean healthcare equipment market.
Looking ahead, Tomocube is expected to see a significant increase in revenue, with analysts forecasting a jump from KRW 11,306,726,320 to KRW 23,200,000,000 in the current fiscal year. However, the company's operating cash flow remains negative at KRW -6,754,417,130, and free cash flow is also negative at KRW -4,070,681,630, indicating that the company is not yet generating sufficient cash from operations to fund its activities.
Risk factors for Tomocube include the potential for dilution, although the risk is currently assessed as low. The company has not issued additional shares recently, and there are no immediate filing-based liquidity or dilution flags. However, the company's high debt-to-equity ratio of 0.03 suggests that it is not heavily leveraged, which is a positive sign for financial stability.
Recent events include the release of the latest financial statements, which show continued losses but also a strong cash position. There are no recent filings or transcripts indicating significant changes in the company's strategic direction or operational performance.
- Tomocube has a strong liquidity position with a current ratio of 23.15, indicating a robust ability to meet short-term obligations.
- The company is currently unprofitable, with a net loss of KRW 4,810,012,370 and a negative ROE of -12.4%.
- Analysts expect a significant revenue increase in the current fiscal year, forecasting a jump to KRW 23,200,000,000.
- The company's revenue is concentrated in a single business segment, increasing exposure to market-specific risks.
- Tomocube's high price-to-book ratio of 16.04 suggests the market is valuing the company at a premium, potentially reflecting expectations of future growth.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Ev To Revenueenterprise_value / revenue
- Tomocube Inc Market data — financials · 2026-05-26
- Tomocube Inc Market data — analyst estimates · 2026-05-26